

# Phase 1/2a Study for IPG7236 in Patients With Advanced Solid Tumors

NCT05142592

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1, Phase 2
<b>Sponsor</b>	Nanjing Immunophage Biotech Co., Ltd
<b>Enrollment</b>	196 participants

## Key Eligibility Criteria

---

### Inclusion (30)

- A written informed consent must be signed prior to performing any study procedures.
- Male or females 18 years or older.
- Diagnosis of advanced or recurrent, histologically or cytologically confirmed, a solid malignancy that is either metastatic or unresectable.
- Part 1 Dose Escalation: all solid tumor types.
- Part 2 Dose Expansion: the following tumor types are tentatively planned for expansion. It may be modified based on the results from the dose escalation phase.

... and 25 more (see full listing online)

### Exclusion (24)

- Subjects with primary malignancy of the central nervous system or malignancies related to human immunodeficiency virus (HIV) or solid organ transplant.
- Subjects who have not recovered from all toxic effects from prior antitumor therapy or surgical procedures, defined as toxicities (other than alopecia) not yet resolved to Grade d 1 according to NCI CTCAE v5.0.
- Subjects with recent prior therapy defined as
- Any investigational or Food and Drug Administration (FDA)-approved anti-cancer drug within 14 days or 5 half-lives, whichever is longer, prior to the first dose of study drug.
- Any radiotherapy, chemotherapy, targeted therapy or immunotherapy within 14 days or major surgery within 28 days or anti-neoplastic antibody or nitrosoureas/mitomycin C within 42 days prior to the first dose of study drug

... and 19 more (see full listing online)

## Locations (7 total)

---

Providence Portland Medical Center, Portland, Oregon, United States  
NEXT Oncology, Austin, Texas, United States  
The First Affiliated Hospital Nanchang Univeristy, Nanchang, Jiangxi, China  
... and 4 more locations

---

<https://clinicaltrials.gov/study/NCT05142592>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).